Adoption has grown from a negligible amount to roughly 15% over the past five years, said David West, CEO of Proscia, a digital pathology company, and a Q2 Solutions partner. The Digital Pathology Association notes that adoption in recent years has been brisk, hovering between 27% and 37% growth from 2021 to 2023, with the pandemic serving as an accelerant. Growth is cooling but is still brisk. According to Proscia’s 2023 Life Sciences Digital Pathology Adoption Survey, 70% of life sciences organizations were using digital pathology, with an additional 53% of t…
The growing influence of digital pathology in preclinical R&D: Spotlight on Proscia’s Concentriq
As drug discovery evolves, digital pathology platforms are playing a vital role in streamlining preclinical R&D processes and accelerating drug discovery. Proscia‘s Concentriq for Research reflects this trend.
Earlier this year, we profiled PathAI’s AISight, a digital pathology platform designed to support AI-driven research. To learn more about Proscia’s digital pathology technology, we caught up with Nathan Buchbinder, co-founder and chief product officer at Proscia, who discussed how the Concentriq for Research digital pathology platform streamlines the preclinical R&D process and accelerates studies. In the following Q&A, he highlights the benefits of Good Laboratory Practice (GLP) compliance, the role of AI in unlocking new insights and how the platform facilitates collaboration…